Clinical Pharmacology & Therapeutics
May 28, 2026
Gia Han Le, Sabrina Wong, Danica E. Johnson et al.
Major depressive disorder (MDD) and treatment-resistant depression (TRD) remain leading causes of disability, providing the impetus for receptor-level treatment strategies beyond monoamine reuptake. The serotonin 5-HT2B receptor (5-HT2BR) is uniquely positioned at the interface of central-antidepressant mechanisms and peripheral cardiac risks. Herein, we reviewed preclinical, translational and...
May 27, 2026
James Phelps
A new randomized trial found serial intravenous ketamine was not significantly more effective than the active placebo midazolam in reducing depressive symptoms or improving quality of life. While the study may have been underpowered due to a small sample size (n=63), the improvement in MADRS scores fell short of the minimal clinically important difference. The study faced blinding failures,...
Psychotherapy and Psychosomatics
May 27, 2026
Lea J. Mertens, Felix Betzler, Manuela Brand et al.
Psilocybin shows promise for treatment-resistant depression (TRD), but long-term data are limited. This study examined the antidepressant effect of one or two psilocybin doses with adjunct psychotherapy in TRD until twelve months. This is a naturalistic follow-up of a phase 2b, randomized, active placebo-controlled trial, where participants were randomized to receive two drug administrations...
European Journal of Psychotraumatology
May 26, 2026
Xiuchuan He, Yuanli Ren, Qian Bian et al.
Background: Depression and anxiety are common mental health problems that frequently co-occur with trauma-related disorders and often develop following traumatic or stressful events, substantially impairing quality of life. Mindfulness-based interventions have been shown to reduce these symptoms; however, their widespread implementation is often limited by poor accessibility and low adherence....
Expert Opinion on Investigational Drugs
May 26, 2026
Mina Takahashi, Richard C. Shelton
INTRODUCTION: Bipolar depression with acute suicidal ideation and behavior (ASIB) is a life- threatening manifestation of bipolar disorder (BD), with a suicide risk higher than that in other psychiatric disorders and the general population. Rapid and effective interventions are critical, as traditional therapies are often slow and frequently insufficient. Currently, no drug is approved by the...
Australian & New Zealand Journal of Psychiatry
May 26, 2026
Yash Giri, Paul Furst, Colleen Loo et al.
1 citation
Treatment-resistant depression is a condition with significant morbidity, despite the current standard of treatment, including traditional pharmacotherapy, psychotherapy, augmentation strategies and electroconvulsive therapy. While novel therapies have emerged, such as ketamine/esketamine, transcranial magnetic stimulation and psilocybin-assisted therapy, the uptake of these treatments is...
Journal of Nursing Education and Practice
May 25, 2026
Albany LaGore, Nadine Kridli, Ron Piscotty et al.
Background: Adolescents with neurological disorders (NDs) experience significantly higher rates of depression, anxiety, or both relative to adolescents in the general population. The purpose of this systematic narrative review was to examine the existing literature evaluating the effects of mindfulness-based interventions (MBIs) on anxiety, depression, or both among adolescents with a known ND....
Biomedicines
May 23, 2026
Dominik Jucha, Michał Klimas, Dominika Wiśniewska et al.
Background/Objectives: Bipolar disorder affects about 40 million people worldwide, and the greatest burden of the disease is associated with depressive episodes. About 25% of patients experience drug-resistant depression, in which standard treatment turns out to be insufficient, and monotherapy often does not bring full remission. Despite the use of second-generation antipsychotics, the...
Psychopharmacology
May 22, 2026
Wei-Chen Lin, Li-Kai Cheng, Tung-Ping Su et al.
Background: Studies have demonstrated that subanesthetic-dose ketamine may modulate the functioning of specific depression-related brain regions, particularly the anterior cingulate cortex and prefrontal cortex. However, how subanesthetic-dose ketamine alters the global and regional graph theory metrics of resting-state functional connectivity in patients with treatment-resistant depression...
Therapeutic Advances in Psychopharmacology
May 22, 2026
Liliana Patarroyo-Rodriguez, Vanessa K. Pazdernik, Jennifer L. Vande Voort et al.
Background: Ketamine and esketamine ((es)ketamine) rapidly reduce depressive symptoms and suicidal ideation (SI) in treatment-resistant depression (TRD), but whether early SI improvement during the acute phase of the treatment predicts reduced suicide-associated emergency department (SAED) visits over the longer term remains unclear. Objectives: To examine whether early improvements in SI,...